Aridis Pharmaceuticals (NASDAQ:ARDS) & Cartesian Therapeutics (NASDAQ:RNAC) Financial Analysis
Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report) and Aridis Pharmaceuticals (NASDAQ:ARDS – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability and institutional ownership. Insider & Institutional Ownership 87.0% of Cartesian […]
More Stories
Stifel Nicolaus Increases Doman Building Materials Group (TSE:DBM) Price Target to C$9.25
Doman Building Materials Group (TSE:DBM – Get Free Report) had its price target raised by equities research analysts at Stifel...
Analyzing Tucows (NASDAQ:TCX) and Toast (NYSE:TOST)
Tucows (NASDAQ:TCX – Get Free Report) and Toast (NYSE:TOST – Get Free Report) are both computer and technology companies, but...
FY2025 EPS Estimates for UMH Properties, Inc. Reduced by B. Riley (NYSE:UMH)
UMH Properties, Inc. (NYSE:UMH – Free Report) – Equities researchers at B. Riley decreased their FY2025 earnings per share estimates...
Analysts Issue Forecasts for The AES Co.’s Q1 2025 Earnings (NYSE:AES)
The AES Co. (NYSE:AES – Free Report) – Investment analysts at Zacks Research lifted their Q1 2025 earnings per share...
Zacks Research Weighs in on T-Mobile US, Inc.’s Q3 2026 Earnings (NASDAQ:TMUS)
T-Mobile US, Inc. (NASDAQ:TMUS – Free Report) – Stock analysts at Zacks Research raised their Q3 2026 earnings per share...
Truist Financial Cuts Viper Energy (NASDAQ:VNOM) Price Target to $54.00
Viper Energy (NASDAQ:VNOM – Free Report) had its price target cut by Truist Financial from $55.00 to $54.00 in a...